Health and economic benefits of increased β-blocker use following myocardial infarction

JAMA

Volumn 284, Issue 21, 2000, Pages 2748-2754

  Phillips, Kathryn A ^a   Shlipak, Michael G ^b,c   Coxson, Pam ^b   Heidenreich, Paul A ^d   Hunink, M G Myriam ^e,f   Goldman, Paula A ^e   Williams, Lawrence W ^e   Weinstein, Milton C ^e   Goldman, Lee ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; COMPUTER SIMULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG USE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0034614172     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.284.21.2748     Document Type: Article

References (51)

1. Beta blockade during and after myocardial infarction
2. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
3. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction
4. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
5. Effect on mortality of metoprolol in acute myocardial infarction
6. A randomized trial of propranolol in patients with acute myocardial infarction, I: Mortality results
7. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction
8. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction
9. Underutilisation of beta-blockers after acute myocardial infarction
10. Forecasting coronary heart disease incidence, mortality, and cost
11. The recent decline in mortality from coronary heart disease, 1980-1990
12. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction
13. The urgent need to improve health care quality
14. Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease
15. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension
16. Long-term impact of smoking cessation on the incidence of coronary heart disease
17. Expected gains in life expectancy from various coronary heart disease risk factor modifications
18. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of heart disease
19. Cost and health implications of cholesterol lowering
20. Impact and cost-effectiveness of smoking interventions
21. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications
22. The cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults
23. Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels
24. The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines
25. Reporting cost-effectiveness studies and results
26. Effect of beta-blockade on mortality in patients with heart failure
27. Cardiologists' practices compared with practice guidelines
28. Treatment of myocardial infarction in the United States (1990 to 1993)
29. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992
30. Overview of results of randomized clinical trials in heart disease
31. Foundations of cost-effectiveness analysis for health and medical practices
32. Quality of life before and during anti-hypertensive treatment
33. Erectile dysfunction and cardiovascular disease
34. Cost-effectiveness of captopril therapy after myocardial infarction
35. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals
36. Coste-ffectiveness of extending mammography screening programs to women 40-49 years old
37. Costs and effectiveness of routine therapy with long-term beta-andrenergic antagonists after acute myocardial infarction
38. National patterns and predictors of beta-blocker use in patients with coronary artery disease
39. Timeliness and quality of care for elderly patients with acute myocardial infarction under health maintenance organization vs fee-for-service insurance
40. Knowledge and practices of generalists and specialist physicians regarding drug therapy for acute myocardial infarction
41. Outcome of acute myocardial infarction according to the specialty of the admitting physician
42. Effect of antihypertensives on sexual function and quality of life
43. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study
44. Physicians and the pharmaceutical industry
45. Trends in antihypertensive drug use in the United States
46. Improving the quality of care for Medicare patients with acute myocardial infarction
47. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team